Brief: Talaris Therapeutics Reports Q2 Loss Per Share Of $0.44

Tourmaline Bio

15/08/2022 12:50

Aug 15 (Reuters) - Talaris Therapeutics Inc  TALS.O :
    * TALARIS THERAPEUTICS ANNOUNCES SECOND QUARTER FINANCIAL
RESULTS
AND CORPORATE UPDATE
    * Q2 LOSS PER SHARE $0.44
    * STRONG CASH BALANCE WITH EXPECTED RUNWAY THROUGH 2024
    * FINISHED Q2 WITH $207.1 MILLION IN CASH, CASH EQUIVALENTS
AND
MARKETABLE SECURITIES

Source text for Eikon:  ID:nGNX8qNBQJ 
Further company coverage:  TALS.O 

 ((Reuters.Briefs@thomsonreuters.com;;))